News

Harnessing the Power of Transcriptomics for Drug Discovery

Harnessing the Power of Transcriptomics for Drug Discovery

Unlocking Drug Discovery Through Transcriptomics

Join our upcoming free webinar to explore the groundbreaking role of transcriptomics assays in transforming the landscape of data-driven drug discovery. This session promises invaluable insights into mechanism-of-action clustering and pathway analysis through comprehensive compound profiling in primary human cells.

A Deep Dive Into Mechanism-of-Action Clustering

During this engaging presentation, industry experts will delve into how transcriptomic data uncovers critical insights into downstream effects and off-target consequences of RNAi therapeutics. By utilizing high-resolution, genome-wide expression data, we can develop more predictive models that propel our understanding of therapeutic safety and efficacy.

The Challenges of Traditional Discovery Approaches

Traditional drug discovery methods often force researchers into a dilemma: opting for deep biological resolution on a few perturbations or trading off depth for broad screens with limited endpoints. This upcoming webinar aims to address this challenge by showcasing high-throughput transcriptomics assays, enabling genome-wide expression profiling at an industrial scale. Such innovative approaches support the discovery of mechanisms of action, thorough pathway analysis, and enhanced assessments of therapeutic safety.

Enhancing Predictive Models in Early-Stage Research

Attendees will uncover how broad compound profiling in primary human cells not only facilitates clustering by mechanism but also reveals shared and distinct regulatory programs. This depth of data enriches the screening process significantly. Furthermore, the discussion will highlight how transcriptomic responses to perturbations unveil off-target effects, moving the conversation beyond traditional knockdown measurements.

Key Insights From Industry Experts

Our featured speakers will demonstrate how high-resolution transcriptomic data enhances predictive toxicology, empowering large-scale screening that balances both breadth and depth in early-stage research. This combination is vital in helping researchers adapt quickly to new therapeutic strategies.

How to Participate

We invite you to register for this enlightening webinar on the transformative impact of transcriptomics assays in drug discovery. Listen to leading experts from the industry who will share their insights and experiences. Participants will engage with George Pilitsis, Director of Product; Ayla Ergun, Sr. Director of Computational Biology & AI; and Kurt Cox, Senior Engineer, during this live session.

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., stands out as a premier provider of educational webinars and digital content for the global life sciences, food, healthcare, and medical device sectors. Each year, professionals from pharmaceutical, biotechnology, food, and healthcare industries turn to Xtalks for access to quality content, enabling them to stay updated on industry trends, regulations, and opportunities.

This platform allows industry practitioners to gain perspectives on critical issues from leading thought leaders and service providers, ensuring they remain on the cutting edge of advancements in their fields.

Contact Us

If you're interested in learning more or need further assistance, please reach out. Our team is here to help you navigate the complexities of drug discovery and development.

Frequently Asked Questions

What is the focus of the upcoming webinar?

The webinar will focus on how transcriptomics assays are revolutionizing drug discovery by providing insights into mechanism-of-action clustering and therapeutic safety assessments.

Who are the featured speakers at the webinar?

The session will feature George Pilitsis, Ayla Ergun, and Kurt Cox, who are experts in their respective fields.

How can I register for the webinar?

You can register directly on the Xtalks platform. Look for the event titled "Profiling Biology at Scale with DRUG-seq" to sign up.

What makes transcriptomics essential for drug discovery?

Transcriptomics provides crucial data that can lead to better understanding of drug interactions, mechanisms of action, and potential off-target effects, thereby enhancing predictive toxicology.

What industries does Xtalks cater to?

Xtalks serves various sectors, including pharmaceuticals, biotechnology, food, healthcare, and medical devices, offering relevant insights and educational content.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 85

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 136

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 171

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 203

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 139

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Nord Anglia's Private Schools Shine in 2026 National Rankings

Updated Category News Views 363

Nord Anglia's Schools Excel in National Rankings Nord Anglia schools ranked in the top 0.5 to 2% nationally Nord Anglia Education is proud to announce that its schools across the United States have achieved remarkable positions among the leading private schools nationwide, according to the latest Niche rankings for 2026. Unveiling Exceptional Educational Achievements This...

Continue Reading
Ingevity's Leadership Change: New Interim CEO Appointed

Updated Category News Views 151

Ingevity Announces CEO Transition Ingevity Corporation (NYSE: NGVT) has experienced a significant change in its leadership with John Fortson stepping down as president and chief executive officer. Following his departure, the company has entrusted board director Luis Fernandez-Moreno with the role of interim president and CEO while a search is underway for a permanent...

Continue Reading
Projected Growth of Supply Chain Security Market by 2030

Updated Category News Views 165

Growth Prospects of the Supply Chain Security Market The global Supply Chain Security Market is set for significant growth, projected to reach USD 5.14 billion by 2030, up from USD 2.52 billion in 2024. The expected compound annual growth rate (CAGR) during this period is 12.6%, indicating robust expansion in a field that safeguards vital supply chain operations. Scope...

Continue Reading
KLA Corporation's Impressive Fiscal 2026 Q2 Performance Review

Updated Category News Views 249

KLA Corporation's Fiscal 2026 Quarter Two Results Overview KLA Corporation (NASDAQ: KLAC) has reported robust financial results for the second quarter of fiscal year 2026, significantly surpassing expectations. These results underline the company’s powerful position within the semiconductor manufacturing industry. Financial Highlights Revenue Performance The company's...

Continue Reading
Heidi Hunter Steps Up as Vice Chair at Bavarian Nordic Board

Updated Category News Views 152

Heidi Hunter's New Role at Bavarian Nordic Recently, Bavarian Nordic A/S (Copenhagen: BAVA) announced an exciting development by appointing Heidi Hunter as the new Vice Chair of its Board of Directors. This decision follows the recent elevation of Anne Louise Eberhard to Chair, marking a shift in leadership aimed at steering the company forward in the pharmaceutical...

Continue Reading